SITEMAP
Pages
Articles
- Cell Therapy to Address Treatment Gap Between Pain Management and End-stage Surgery for Chronic Degenerative Diseases
- Dr. Manish Gupta joins the GIDOA-03 team
- Research on pain management, the treatment gap, and cellular therapy
- The FDA approval process is important for patient safety and cell therapy research
- Two new employees join GID BIO team
- GID BIO CEO William Cimino, PhD, moderates panel at recent IFATS conference
- FDA announces consolidation of regulatory oversight responsibilities for fat transfer devices that process adipose tissue for return to the body
- New trial site, the University of Pittsburgh Medical Center, joins GID BIO’s pivotal Phase III trial
- Professional athletes-turned physicians discuss the importance of cell therapy on The Ortho Show
- AdventHealth Orlando joins as newest trial site in pivotal Phase III trial
- Wake Forest Medical School added as newest site in pivotal Phase III trial
- UC Davis joins as trial site in pivotal Phase III trial
- OrthoCarolina joins as trial site in pivotal Phase III trial
- Beyond drugs and surgery: changing medicine as we know it
- GID on Track to Treat Pain and Function Associated with Knee Osteoarthritis
- Autologous stromal vascular fraction (SVF) cells from adipose tissue for knee osteoarthritis
- Orlando Medical News features GID BIO’s cellular therapy and pivotal/Phase III clinical trial
- San Antonio Business Journal features GID BIO’s cellular therapy and pivotal/Phase III clinical trial principal investigator, Dr. Jaime Garza: “On the forefront of new cell therapy research, an Alamo City surgeon has a key role in moving new medical technology to market”
- Late-stage biotech GID BIO wins funding from Richard King Mellon Foundation…
- Denver Business Journal features GID BIO…
- Denver Business Journal features GID BIO: “Colorado biotech firm’s new cell therapy could eliminate the need for knee replacements”
- Former Yahoo! Chairman, Wall Street Titan Roy J. Bostock Joins GID BIO as Chair
- Tulane University School of Medicine announces pivotal / Phase III clinical trial for patients with knee osteoarthritis
- Aerospace to cellular therapy: How GID BIO’s CEO used his expansive engineering background to help design a scalable device for cellular therapy
- Beyond knee osteoarthritis: GID explores cellular therapy to potentially treat dermal, organ and more musculoskeletal diseases
- GID BIO addresses a growing need for cost-effective U.S. osteoarthritis treatments
- American Journal of Sports Medicine publishes results of a clinical trial for treating osteoarthritis knee pain
- GID BIO seeks up to USD 25m to support cellular therapy platform, CEO says
- An interview with William Cimino, PhD, CEO GID BIO, International Federation for Adipose Therapeutics and Science (IFATS) Annual Conference in Marseille, France
- Physicians: advancing the future of evidence-based cellular therapy could increase quality of life for 14 million US adults suffering from knee osteoarthritis
- Leaders come together for the first time to advance the field of cellular medicine and its treatment of pain and function associated with knee osteoarthritis
- Device and cellular therapy could lead to a major development in the treatment of pain and function associated with knee osteoarthritis for 14 million US adults
- GID BIO aims to make treatment for pain and function associated with knee osteoarthritis accessible to millions with a single-use device and point-of-care therapy
- Precision medicine could improve treatment for 14 million U.S. adults with knee osteoarthritis
- American Journal of Sports Medicine to publish results of a clinical trial
- Device and point-of-care therapy intended to treat pain and function could soon help knee osteoarthritis patients
- FDA compliant trial for cellular implant therapy could mean a major development in the treatment of pain associated with knee osteoarthritis
- 6 Orthobiologic Companies Move Clinical Trials Forward
- GID BIO aims to close a healthcare gap with the launch of a cost-effective treatment for those suffering from osteoarthritis
- GID BIO Completes Trial of Stromal Cells to Treat Knee OA
- GID BIO’s results in FDA compliant, multi-site, randomized, placebo-controlled Phase IIb clinical trial support an evidence-based, data-driven approach to treat pain-management caused by osteoarthritis of the knee
- GID BIO, a cellular therapy company, moves a step closer to potentially helping relieve the $200 billion osteoarthritis burden on the U.S. healthcare system
- Interventional Orthopedics and Cell-based Medicine
- Initial safety and feasibility of cellular therapy
- Initial safety and feasibility of cellular therapy
